CN1651004A - Compound ginseng tea preparation for treating chronic pelvic cavity inflammation and its preparation method - Google Patents
Compound ginseng tea preparation for treating chronic pelvic cavity inflammation and its preparation method Download PDFInfo
- Publication number
- CN1651004A CN1651004A CN 200410101541 CN200410101541A CN1651004A CN 1651004 A CN1651004 A CN 1651004A CN 200410101541 CN200410101541 CN 200410101541 CN 200410101541 A CN200410101541 A CN 200410101541A CN 1651004 A CN1651004 A CN 1651004A
- Authority
- CN
- China
- Prior art keywords
- extract
- rhizoma cyperi
- preparation
- volatile oil
- catechu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating chronic pelvic inflammation is prepared from 5 Chinese-medicinal materials including catechu, flavescent sophora root, dandelion herb, cyperus tuber, etc. Its preparing process is also disclosed.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of preparation for the treatment of chronic pelvic inflammatory disease and preparation method thereof, said preparation claims the compound ginseng tea preparation again.
Technical background
Chronic pelvic inflammatory disease is meant women's internal genitalia (comprising uterus, fallopian tube, the other connective tissue in palace and pelvic peritoneum etc.) inflammation, can be confined to a position, also can relate to whole internal genitalia, the chronic pelvic inflammatory disease cardinal symptom is that lower abdomen and waist are ached, and often increases with menoxenia and leukorrhagia.This disease course of disease is long, easily outbreak repeatedly, also can the secondary dysmenorrhea, infertile, ectopic pregnancy etc., chronic pelvic inflammatory disease is secondary to acute pelvic inflammatory disease mostly, causes because of treatment is not thorough, the state of an illness is delayed or patient's body constitution is relatively poor, and chronic pelvic inflammatory disease is because long-term inflammatory stimulus, easily cause the surrounding tissue adhesion, and obstinate, outbreak repeatedly, and influence women's operate as normal and life and physical and mental health.Doctor trained in Western medicine adopts antibiotic therapy to this disease more, and anti-inflammatory drug is difficult for entering, and inflammation then is difficult to control, and curative effect is not satisfied, and antibiotic therapy tends to cause some side effect.Chinese medicine thinks that chronic pelvic inflammatory disease mainly is owing to invade in the pathogenic factor, causes damp and hot silt poison, and with the passing of time then QI and blood is retarded by silt, and channels is become estranged, and forms the silt piece, so treatment needs based on promoting flow of QI and blood, eliminating damp-heat.Chronic pelvic inflammatory disease is owing to there is the characteristic of recurrence repeatedly, so it is cumbersome that treatment is got up, when cooperating physiotherapy, to take Chinese medicine, Therapeutic Method has oral drugs and external treatment (physiotherapy, pharmacotherapy) at present, inflammatory tissue comes off though the physiotherapy in the external treatment can make, cervical mucosa is newborn repairs, but side effect such as hemorrhage, that water sample oozes out are arranged, also can shrink and make narrow, the adhesion of cervical canal, and treatment must be carried out in hospital because of scar tissue.Pharmacotherapy in the external treatment belongs to the non-invasive treatment method in clinical rather well received and attention because of directly acting on disease sites, the dosage form of clinical report application at present has fumigation and washing agent, powder, suppository, unguentum, paste etc., but these dosage forms often big, the poor permeability of medicine coated face, mucosa is had stimulation, and shortcoming such as the inconvenience of use is arranged all.
In patent retrieval, do not find the report of any relevant compound ginseng tea preparation of the present invention.
Summary of the invention
The objective of the invention is to disclose a kind of good effect, easy to use, the compound ginseng tea preparation of the treatment chronic pelvic inflammatory disease that side effect is little.
Compound ginseng tea preparation raw material medicine disclosed by the invention is made up of catechu 1-2 weight portion, Radix Sophorae Flavescentis 4-8 weight portion, Herba Taraxaci 6-12 weight portion, Rhizoma Cyperi 3-6 weight portion, Cortex Ailanthi 4-8 weight portion.
Another object of the present invention is the preparation method that discloses above-mentioned compound ginseng tea preparation.
The present invention is achieved through the following technical solutions:
One, preparation method
1. process recipes:
(1) gets Rhizoma Cyperi, be ground into coarse powder, extract volatile oil with steam distillation, get Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add 10-20 and doubly measure in HP-β-CD saturated solution 40 ℃-50 ℃ of temperature, stirred 3 hours, restir is 2 hours under the room temperature, and placement is spent the night, and filters, cold drying gets the Rhizoma Cyperi volatile oil clathrate.
(2) get catechu and doubly measure the 40%-80% alcohol reflux three times with 6-8, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, and vacuum drying gets Catechu extract.
(3) getting Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi adds 8 times of water gagings and decocts secondaries, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leave standstill, filter, decompression filtrate recycling ethanol also concentrates, vacuum drying, the extract of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi.
2. preparation prescription:
The tablet formulation prescription is formed: Rhizoma Cyperi volatile oil clathrate 1.1-3.5 weight portion, Catechu extract 3.2-7.2 weight portion, the extract 13.5-29 weight portion of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, pharmaceutic adjuvant 6.9-12.7 weight portion;
The capsule formulation prescription is formed: Rhizoma Cyperi volatile oil clathrate 1.1-3.5 weight portion, and Catechu extract 3.2-7.2 weight portion, the extract 13.5-29 weight portion of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, pharmaceutic adjuvant 1.8-7.2 weight portion,
The granular preparation prescription is formed: Rhizoma Cyperi volatile oil clathrate 1.1-3.5 weight portion, Catechu extract 3.2-7.2 weight portion, the extract 13.5-29 weight portion of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, pharmaceutic adjuvant 31.6-50.6 weight portion;
The oral liquid formulations prescription is formed: Rhizoma Cyperi volatile oil clathrate 1.1-3.5 weight portion, and Catechu extract 3.2-7.2 weight portion, the extract 13.5-29 weight portion of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, pharmaceutic adjuvant 2.5-3.5 weight portion:
3. formulation preparation:
Preparation tablets: get the Rhizoma Cyperi volatile oil clathrate of above-mentioned weight portion, Catechu extract, the extract of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and pharmaceutic adjuvant, the preparation granule, tabletting promptly gets compound ginseng tea tablet of the present invention;
The capsule preparation: get the Rhizoma Cyperi volatile oil clathrate of above-mentioned weight portion, Catechu extract, the extract of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and pharmaceutic adjuvant, the preparation granule, encapsulated, promptly get compound ginseng tea capsule of the present invention;
The granule preparation: get the Rhizoma Cyperi volatile oil clathrate of above-mentioned weight portion, Catechu extract, the extract of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and pharmaceutic adjuvant, the preparation granule, packing promptly gets compound ginseng tea granule of the present invention;
The oral liquid preparation: get the Rhizoma Cyperi volatile oil clathrate of above-mentioned weight portion, Catechu extract, the extract of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi adds the water heating for dissolving, filters, and adds pharmaceutic adjuvant, adds water to full dose, promptly gets compound ginseng tea oral liquid of the present invention;
Catechu in the preparation of the present invention has removing dampness and holds back the skin ulcer effect, Radix Sophorae Flavescentis has that the heat clearing away bath is wet, parasite killing, diuresis effect, Herba Taraxaci has the thermal detoxification of asking, dispersing swelling and dissipating binds, inducing diuresis for treating stranguria syndrome effect, Rhizoma Cyperi has promoting QI circulation for relieving depression, menstruction regulating and pain relieving effect, Cortex Ailanthi has heat extraction, dampness, astringing intestine to stop diarrhea, hemostasis, disinsection efficiency.More than each medicine share, eliminating damp-heat power is strong, holding concurrently can the circulation of qi promoting blood stasis dispelling, pain relieving all has remarkable effect to damp and hot stasis of blood knot with the pelvic inflammatory disease that two kinds of different pathogenesis of QI stagnated by cold cause, and can play the effect for the treatment of both the principal and secondary aspects of a disease.The preparation of prescription compatibility of medicines of the present invention has the effect of heat-clearing and toxic substances removing, removing damp and stopping pain, is mainly used in profuse leukorrhea, yellow skin, dysmenorrhea and chronic pelvic inflammatory disease due to the damp-heat accumulation person that sees the above-mentioned symptom.
HP-β-CD is an excipient substance newly developed in the world in recent years, it has overcome the inherent shortcoming of β-CD, good water solubility, the heat stability height, be low toxicity, safe and effective medicine solubilizing agent, stabilizing agent and absorption enhancer, HP-β-CD is improving medicine stability, increase the not dissolubility of soluble drug of water, reduce the zest of medicine to the people, aspects such as raising bioavailability of medicament have important effect, HP-β-CD metabolism that is not decomposed basically in human body is not simultaneously accumulated yet, and the application of HP-β-CD at present more and more obtains paying close attention to.The present invention carries out enclose with Rhizoma Cyperi volatile oil with HP-β-CD, can improve the stability of Rhizoma Cyperi volatile ingredient, increases the dissolving and the dissolution rate of medicine, improves bioavailability, makes the volatile oil solidification help preparing solid orally ingestible simultaneously.
Dosage form of the present invention can be acceptable tablet, capsule, granule, oral liquid on the pharmaceutics.
Pharmacological evaluation proof compound ginseng tea preparation of the present invention has pharmacological action preferably.
Two, the assay of catechin and epicatechin in the Catechu extract
Reagent: Catechu extract of the present invention (Tianzhijiao Medication Development Co., Ltd., Guangdong's prepared in laboratory).
1. chromatographic condition: diamonsil C18 post (150mm * 3mm, 5 μ m), mobile phase of acetonitrile and water (10: 90); Detect wavelength: 280nm; Flow velocity: 1ml/min.
2. assay method: precision takes by weighing catechin reference substance and epicatechin reference substance, and with 50% methanol wiring solution-forming, making catechin content is 0.4mg/ml, and epicatechin content is 0.03mg/ml; Get this product 0.1g, put in the 100ml volumetric flask,, and add 50% methanol constant volume, shake up, filter, i.e. sample solution to scale with 50% methanol supersound process 15 minutes; Get reference substance solution and sample solution 10 μ l respectively, inject high performance liquid chromatograph, measure and calculate, the results are shown in Table 1.
The assay of table 1 extract
The total percentage composition (%) of group catechin (%) epicatechin (%)
Catechu extract 1 43.2 2.7 45.9
Catechu extract 2 43.6 2.7 46.3
Catechu extract 3 44.0 2.8 46.8
The result shows that the gross weight percentage composition of catechin and epicatechin in three batches of Catechu extracts of prepared produced according to the present invention is all greater than 45%.
Three, pharmacological testing
Reagent and animal: compound ginseng tea preparation of the present invention (Tianzhijiao Medication Development Co., Ltd., Guangdong's laboratory provides);
HUAHONG PIAN (Guangxi premium pharmaceutcal corporation, Ltd); Staphylococcus albus, escherichia coli, green
Pus bacillus, staphylococcus epidermidis, Bacillus proteus are carried by Nat'l Pharmaceutical ﹠ Biological Products Control Institute
Supply; Mice is provided by Guangdong Province's animal center.
1. antibacterial experiment
The filter paper method is measured bacteriostasis: the filter paper of cut-off footpath 6mm, put into drug solution and soak 16h, 120 ℃ of following moist heat sterilizations are standby. respectively get 0.5ml and corresponding solid medium with above-mentioned for examination bacterium liquid, make in superclean bench and contain the bacterium flat board, get the filter paper that contains diffusion juice and be attached to and contain on the bacterium flat board, every ware pastes 5, every bacterium is cooked 3 repetitions, antibacterial is put and cultivates 48h in 37 ℃ of biochemical incubators, the inhibition zone size of filter paper behind mensuration 24h, the 48h, and relatively fungistatic effect sees Table 2.
Table 2 pair inhibition effect for the examination strain
For examination strain HUAHONG PIAN compound ginseng tea oral formulations of the present invention
Bacteriostatic diameter (mm) bacteriostatic diameter (mm)
24h 48h 24h 48h
Staphylococcus albus 8.5 8.3 9.5 9.5
Escherichia coli 10.0 10.2 11.0 11.5
Bacillus pyocyaneus 4.5 4.5 6.5 6.0
Staphylococcus epidermidis 8.5 8.0 9.5 9.0
Bacillus proteus 7.5 7.0 9.0 8.5
Above-mentioned pharmacological evaluation shows that compound ginseng tea preparation of the present invention and HUAHONG PIAN relatively have better antibacterial action.
2. antiinflammatory experiment
2.1 xylol causes the inhibitory action of mice ear
60 of female mices (body weight 18-22g) divide 6 groups at random, the blank group, the HUAHONG PIAN group, compound ginseng tea tablet group of the present invention, compound ginseng tea Capsules group of the present invention, the present invention joins tea granule agent group, compound ginseng tea oral liquid group of the present invention, the blank group is irritated stomach and is given 0.5ml normal saline, the HUAHONG PIAN group, compound ginseng tea preparation of the present invention is respectively organized gastric infusion, and (the administration volume is 0.5ml, wherein HUAHONG PIAN is equivalent to crude drug amount 5g/kg, preparation of the present invention is equivalent to 2g crude drug/kg), each organizes administration every day 1 time, successive administration 5 days, behind the 5th day medicine 2 hours, dimethylbenzene 0.02ml is applied to mice left side ear, and mice is put to death in dislocation behind the 1h, cuts two ears, punching is weighed, with left ear and auris dextra sheet weight difference is the swelling degree, calculates swelling rate and suppression ratio, the results are shown in Table 3.
Table 3 xylol causes the inhibitory action (X ± SD) of mice ear
Group Mus number (only) ear swelling rate (%) suppression ratio (%)
Matched group 10 124.51 ± 40.01-
HUAHONG PIAN group 10 82.26 ± 35.93
*33.9
Compound ginseng tea sheet group 10 61.74 ± 32.08 of the present invention
*50.4
Compound ginseng tea Capsules group 10 62.05 ± 35.14 of the present invention
*50.2
Compound ginseng tea groups of grains 10 61.86 ± 34.47 of the present invention
*50.3
Compound ginseng tea oral liquid group 10 61.48 ± 30.27 of the present invention
*50.6
Annotate: compare with the blank group:
*P＜0.05;
*P＜0.01.
Above pharmacological testing shows that compound ginseng tea preparation of the present invention is respectively organized, the equal xylol of HUAHONG PIAN causes mice ear inhibitory action; Each group of compound ginseng tea preparation of the present invention is compared with HUAHONG PIAN, and xylol causes the inhibition better effects if of mice ear.
3. analgesic test
3.1 the mice hot plate is caused the influence of pain effect
60 of female mices (body weight 18-22g) divide 6 groups at random, blank group, HUAHONG PIAN group, compound ginseng tea sheet group of the present invention, compound ginseng tea Capsules group of the present invention, compound ginseng tea granule group of the present invention, compound ginseng tea oral liquid group of the present invention, each group is gastric infusion respectively, dosage is with 2.1, successive administration 5 days, 1h is individually fixed in each Mus in 55 ± 0.5 ℃ the hot-plate instrument after the last administration, to lick the indicator reaction of metapedes as " pain ", mice the results are shown in Table 4 to the hot plate response time bitterly after observing administration.
3.2 the influence of the writhing response that Dichlorodiphenyl Acetate causes
Get 50 of female mices (body weight 18-22g), grouping and medication be with 2.1, successive administration 5 days, and 1h after the last administration, lumbar injection 0.6% acetum 0.2ml/20g body weight is observed the mouse writhing number of times in the 10min, the results are shown in Table 4.
Table 4 analgesic test result (X ± SD)
Group Mus number (only) hot plate pain response time (s) is turned round the body number of times
Blank group 10 11.5 ± 4.0 29.5 ± 4.5
HUAHONG PIAN group 10 16.5 ± 4.2
*19.0 ± 3.9
*
Compound ginseng tea sheet group 10 19.2 ± 3.7 of the present invention
*13.6 ± 3.2
*
Compound ginseng tea Capsules group 10 19.5 ± 4.5 of the present invention
*13.5 ± 3.6
*
Compound ginseng tea granule group 10 19.4 ± 4.3 of the present invention
*13.2 ± 2.5
*
Compound ginseng tea oral liquid group 10 19.1 ± 4.9 of the present invention
*13.5 ± 2.8
*
Annotate: compare with the blank group:
*P＜0.05;
*P＜0.01
Result of the test shows that each group of compound ginseng tea preparation of the present invention has analgesic activity preferably, compares with HUAHONG PIAN, and it is more remarkable that the present invention respectively organizes the analgesic activity of preparation.
Six, specific embodiment
Embodiment 1
(1) crude drug is formed: catechu 120g, Radix Sophorae Flavescentis 480g, Herba Taraxaci 720g, Rhizoma Cyperi 360g, Cortex Ailanthi 480g.
(2) get Rhizoma Cyperi, be ground into coarse powder, extract volatile oil with steam distillation, get Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add in 10 times of amount HP-β-CD saturated solutions 40 ℃-50 ℃ of temperature, stirred 3 hours, restir is 2 hours under the room temperature, and placement is spent the night, and filters, cold drying gets Rhizoma Cyperi volatile oil clathrate 15g.
(3) get catechu with 40% alcohol reflux three times, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, vacuum drying, Catechu extract 54g.
(4) get Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and decoct with water secondary, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leaves standstill, and filters, decompression filtrate recycling ethanol also concentrates, and vacuum drying gets extract 200g.
(5) get the extract of Rhizoma Cyperi volatile oil clathrate, Catechu extract, Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, add lactose 127g, mix, the system granule, drying, granulate adds magnesium stearate 4g, is pressed into 1000, and packing is promptly.
Embodiment 2
(1) crude drug is formed: catechu 120g, Radix Sophorae Flavescentis 480g, Herba Taraxaci 720g, Rhizoma Cyperi 360g, Cortex Ailanthi 480g.
(2) get Rhizoma Cyperi, extract volatile oil with steam distillation, Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add in 12 times of amount HP-β-CD saturated solutions, 40 ℃-50 ℃ of temperature stirred 3 hours, and restir is 2 hours under the room temperature, placement is spent the night, filter, cold drying gets Rhizoma Cyperi volatile oil clathrate 18g.
(3) get catechu with 50% alcohol reflux three times, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, vacuum drying, Catechu extract 52g.
(4) get Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and decoct with water secondary, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leaves standstill, and filters, decompression filtrate recycling ethanol also concentrates, and vacuum drying gets extract 201g.
(5) get the extract of Rhizoma Cyperi volatile oil clathrate, Catechu extract, Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, add starch 29g, the system granule, drying, granulate, encapsulated 1000, packing is promptly.
Embodiment 3
(1) crude drug is formed: catechu 120g, Radix Sophorae Flavescentis 480g, Herba Taraxaci 720g, Rhizoma Cyperi 360g, Cortex Ailanthi 480g.
(6) get Rhizoma Cyperi, extract volatile oil with steam distillation, Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add in 20 times of amount HP-β-CD saturated solutions, 40 ℃-50 ℃ of temperature stirred 3 hours, and restir is 2 hours under the room temperature, placement is spent the night, filter, cold drying gets Rhizoma Cyperi volatile oil clathrate 31g.
(7) get catechu with 60% alcohol reflux three times, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, vacuum drying, Catechu extract 51g.
(8) get Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and decoct with water secondary, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leaves standstill, and filters, decompression filtrate recycling ethanol also concentrates, and vacuum drying gets extract 202g.
(9) get the extract of Rhizoma Cyperi volatile oil clathrate, Catechu extract, Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, add dextrin 316g, the system granule, drying, granulate, packing is promptly.
Embodiment 4
(1) crude drug is formed: catechu 120g, Radix Sophorae Flavescentis 480g, Herba Taraxaci 720g, Rhizoma Cyperi 360g, Cortex Ailanthi 480g.
(2) get Rhizoma Cyperi, extract volatile oil with steam distillation, Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add in 15 times of amount HP-β-CD saturated solutions, 40 ℃-50 ℃ of temperature stirred 3 hours, and restir is 2 hours under the room temperature, placement is spent the night, filter, cold drying gets Rhizoma Cyperi volatile oil clathrate 26g.
(3) get catechu with 60% alcohol reflux three times, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, vacuum drying, Catechu extract 50g.
(4) get Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and decoct with water secondary, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leaves standstill, and filters, decompression filtrate recycling ethanol also concentrates, and vacuum drying gets extract 205g.
(5) get the extract of Rhizoma Cyperi volatile oil clathrate, Catechu extract, Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, add the water heating for dissolving, filter, filtrate adds steviosin 25g, and potassium sorbate 10g adds water to 5000ml, and fill, packing are promptly.
Embodiment 5
(1) crude drug is formed: catechu 80g, Radix Sophorae Flavescentis 320g, Herba Taraxaci 480g, Rhizoma Cyperi 240g, Cortex Ailanthi 320g
(2) get Rhizoma Cyperi, extract volatile oil with steam distillation, Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add in 15 times of amount HP-β-CD saturated solutions, 40 ℃-50 ℃ of temperature stirred 3 hours, and restir is 2 hours under the room temperature, placement is spent the night, filter, cold drying gets Rhizoma Cyperi volatile oil clathrate 16g.
(3) get catechu with 70% alcohol reflux three times, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, vacuum drying, Catechu extract 32g.
(4) get Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and decoct with water secondary, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leaves standstill, and filters, decompression filtrate recycling ethanol also concentrates, and vacuum drying gets extract 145g.
(5) get the extract of Rhizoma Cyperi volatile oil clathrate, Catechu extract, Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, add calcium hydrogen phosphate 104g, mixing, the system granule, drying, granulate adds magnesium stearate 3g, is pressed into 1000, and packing is promptly.
Embodiment 6
(1) crude drug is formed: catechu 80g, Radix Sophorae Flavescentis 320g, Herba Taraxaci 480g, Rhizoma Cyperi 240g, Cortex Ailanthi 320g.
(2) get Rhizoma Cyperi, extract volatile oil with steam distillation, Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add in 10 times of amount HP-β-CD saturated solutions, 40 ℃-50 ℃ of temperature stirred 3 hours, and restir is 2 hours under the room temperature, placement is spent the night, filter, cold drying gets Rhizoma Cyperi volatile oil clathrate 11g.
(3) get catechu with 80% alcohol reflux three times, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, vacuum drying, Catechu extract 36g.
(4) get Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and decoct with water secondary, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leaves standstill, and filters, decompression filtrate recycling ethanol also concentrates, and vacuum drying gets extract 135g.
(5) get the extract of Rhizoma Cyperi volatile oil clathrate, Catechu extract, Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, add dextrin 18g, the system granule, dry, granulate, encapsulated 1000, packing is promptly.
Embodiment 7
(1) crude drug is formed: catechu 80g, Radix Sophorae Flavescentis 320g, Herba Taraxaci 480g, Rhizoma Cyperi 240g, Cortex Ailanthi 320g;
(2) get Rhizoma Cyperi, extract volatile oil with steam distillation, Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add in 20 times of amount HP-β-CD saturated solutions, 40 ℃-50 ℃ of temperature stirred 3 hours, and restir is 2 hours under the room temperature, placement is spent the night, filter, cold drying gets Rhizoma Cyperi volatile oil clathrate 20g;
(3) get catechu with 60% alcohol reflux three times, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, vacuum drying, Catechu extract 35g.
(4) get Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and decoct with water secondary, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leaves standstill, and filters, decompression filtrate recycling ethanol also concentrates, and vacuum drying gets extract 145g.
(5) get the extract of Rhizoma Cyperi volatile oil clathrate, Catechu extract, Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, add the water heating for dissolving, filter, filtrate adds aspartame 20g, and sorbic acid 5g adds water to 5000ml, and fill, packing are promptly.
Embodiment 8
(1) crude drug is formed: catechu 160g, Radix Sophorae Flavescentis 640g, Herba Taraxaci 960g, Rhizoma Cyperi 480g, Cortex Ailanthi 640g;
(2) get Rhizoma Cyperi, extract volatile oil with steam distillation, Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add in 10 times of amount HP-β-CD saturated solutions, 40 ℃-50 ℃ of temperature stirred 3 hours, and restir is 2 hours under the room temperature, placement is spent the night, filter, cold drying gets Rhizoma Cyperi volatile oil clathrate 21g;
(3) get catechu with 50% alcohol reflux three times, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, vacuum drying, Catechu extract 72g.
(4) get Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and decoct with water secondary, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leaves standstill, filter decompression filtrate recycling ethanol and concentrated, vacuum drying gets extract 280g.
(5) get the extract of Rhizoma Cyperi volatile oil clathrate, Catechu extract, Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, add microcrystalline Cellulose 69g, the system granule, drying, granulate adds magnesium stearate 5g, is pressed into 1000, and packing is promptly.
Embodiment 9
(1) crude drug is formed: catechu 160g, Radix Sophorae Flavescentis 640g, Herba Taraxaci 960g, Rhizoma Cyperi 480g, Cortex Ailanthi 640g;
(2) get Rhizoma Cyperi, extract volatile oil with steam distillation, Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add in 12 times of amount HP-β-CD saturated solutions, 40 ℃-50 ℃ of temperature stirred 3 hours, and restir is 2 hours under the room temperature, placement is spent the night, filter, cold drying gets Rhizoma Cyperi volatile oil clathrate 24g;
(3) get catechu with 40% alcohol reflux three times, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, vacuum drying, Catechu extract 70g.
(4) get Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and decoct with water secondary, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leaves standstill, and filters, decompression filtrate recycling ethanol also concentrates, and vacuum drying gets extract 284g.
(5) get the extract of Rhizoma Cyperi volatile oil clathrate, Catechu extract, Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, add starch 72g, the system granule, drying, encapsulated 1000, packing is promptly.
Embodiment 10
(1) crude drug is formed: catechu 160g, Radix Sophorae Flavescentis 640g, Herba Taraxaci 960g, Rhizoma Cyperi 480g, Cortex Ailanthi 640g;
(2) get Rhizoma Cyperi, extract volatile oil with steam distillation, Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add in 18 times of amount HP-β-CD saturated solutions, 40 ℃-50 ℃ of temperature stirred 3 hours, and restir is 2 hours under the room temperature, placement is spent the night, filter, cold drying gets Rhizoma Cyperi volatile oil clathrate 35g;
(3) get catechu with 80% alcohol reflux three times, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, vacuum drying, Catechu extract 69g.
(4) get Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi and decoct with water secondary, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leaves standstill, and filters, decompression filtrate recycling ethanol also concentrates, and vacuum drying gets extract 290g.
(5) get the extract of Rhizoma Cyperi volatile oil clathrate, Catechu extract, Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi, with Icing Sugar 506g, the system granule, drying, granulate, packing is promptly.
Claims (5)
1, a kind of compound ginseng tea preparation for the treatment of chronic pelvic inflammatory disease is characterized in that the raw material medicines in portions by weight proportioning is:
Catechu 1-2 part, Radix Sophorae Flavescentis 4-8 part, Herba Taraxaci 6-12 part, Rhizoma Cyperi 3-6 part, Cortex Ailanthi 4-8 part.
2, a kind of compound ginseng tea preparation for the treatment of chronic pelvic inflammatory disease is characterized in that the said preparation effective ingredient is made up of following parts by weight of component:
Rhizoma Cyperi volatile oil clathrate 1.1-3.5 weight portion, Catechu extract 3.2-7.2 weight portion, the extract 13.5-29 weight portion of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi.
3, according to the compound ginseng tea preparation of claim 1 and 2 described treatment chronic pelvic inflammatory diseases, it is characterized in that its preparation method may further comprise the steps:
(1) gets Rhizoma Cyperi, be ground into coarse powder, extract volatile oil with steam distillation, get Rhizoma Cyperi volatile oil, Rhizoma Cyperi volatile oil with dissolve with ethanol after, add 10-20 and doubly measure in HP-β-CD saturated solution 40 ℃-50 ℃ of temperature, stirred 3 hours, restir is 2 hours under the room temperature, and placement is spent the night, and filters, cold drying gets the Rhizoma Cyperi volatile oil clathrate;
(2) get catechu and doubly measure the 40%-80% alcohol reflux three times with 6-8, each 1 hour, merge ethanol extract, decompression recycling ethanol also concentrates, and vacuum drying gets Catechu extract;
(3) getting Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi adds 8 times of decoctings and boils secondary, 2 hours for the first time, 1 hour for the second time, merge decoction liquor, be concentrated into 2g crude drug/ml, concentrated solution adds ethanol to be made and contains alcohol amount and reach 60%, leave standstill, filter, decompression filtrate recycling ethanol also concentrates, vacuum drying, the extract of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi;
(4) get the Rhizoma Cyperi volatile oil clathrate, Catechu extract, the extract of Radix Sophorae Flavescentis, Herba Taraxaci, Cortex Ailanthi adds proper auxiliary materials preparation cost invention preparation.
4, the compound ginseng tea preparation of treatment chronic pelvic inflammatory disease according to claim 1 is characterized in that said preparation is tablet, capsule, granule, oral liquid.
5, compound ginseng tea preparation according to claim 2, the gross weight percentage composition that it is characterized in that catechin and epicatechin in the Catechu extract is greater than 45%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410101541XA CN100423748C (en) | 2004-12-23 | 2004-12-23 | Compound ginseng tea preparation for treating chronic pelvic cavity inflammation and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410101541XA CN100423748C (en) | 2004-12-23 | 2004-12-23 | Compound ginseng tea preparation for treating chronic pelvic cavity inflammation and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1651004A true CN1651004A (en) | 2005-08-10 |
| CN100423748C CN100423748C (en) | 2008-10-08 |
Family
ID=34869625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410101541XA Expired - Fee Related CN100423748C (en) | 2004-12-23 | 2004-12-23 | Compound ginseng tea preparation for treating chronic pelvic cavity inflammation and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100423748C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526429A (en) * | 2012-02-28 | 2012-07-04 | 陕西中医学院制药厂 | Chinese medicinal preparation for treating nearsightedness and asthenopia and preparation method thereof |
| CN102961648A (en) * | 2012-12-21 | 2013-03-13 | 戴玲玲 | Chinese herbal medicine compound preparation for treating advanced colorectal cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1098916A (en) * | 1993-08-14 | 1995-02-22 | 陈兰君 | Capsule for treating leucorrhoea |
-
2004
- 2004-12-23 CN CNB200410101541XA patent/CN100423748C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526429A (en) * | 2012-02-28 | 2012-07-04 | 陕西中医学院制药厂 | Chinese medicinal preparation for treating nearsightedness and asthenopia and preparation method thereof |
| CN102961648A (en) * | 2012-12-21 | 2013-03-13 | 戴玲玲 | Chinese herbal medicine compound preparation for treating advanced colorectal cancer |
| CN102961648B (en) * | 2012-12-21 | 2014-05-14 | 戴玲玲 | Traditional Chinese medicine compound preparation for treating advanced colorectal cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100423748C (en) | 2008-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522844A (en) | Composition for reducing blood glucose level and use thereof | |
| CN1250277C (en) | Medicine with antiphlogistic, analgetic, microbiostatic and diuretic effects | |
| CN1824101A (en) | Xingsuerchen medicinal preparation and its new preparation method | |
| CN1698757A (en) | Pharmaceutical preparation for treating upper respiratory tract infection and its preparation process and quality control method | |
| CN103690582A (en) | Composition containing dendrobium polysaccharide and atractylodes oil and application thereof | |
| CN1651004A (en) | Compound ginseng tea preparation for treating chronic pelvic cavity inflammation and its preparation method | |
| CN101991577A (en) | Novel mental medicinal composition | |
| CN1966001A (en) | Medicament for treating inflammation and preparation method thereof | |
| CN1887328A (en) | Chinese medicine composition and its prepn process and quality control method | |
| CN1748772A (en) | Acne removing preparation and new preparing method | |
| CN1660353A (en) | Gel of Chinese traditional medicine for treating cervicitis, colpitis and preparing method | |
| CN100475236C (en) | Medicine composition for treating women's pulvic infection, prepn process and use thereof | |
| CN1954841B (en) | Medicine for treating chronic pharyngitis | |
| CN1308019C (en) | Chinese medicinal composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN101450117A (en) | Rheumatism treatment technique | |
| CN1293893C (en) | Gel of Chinese traditional medicine and preparation method | |
| CN1775258A (en) | Womb-warming pregnancy-aiding preparation and new preparing method | |
| CN1772234A (en) | Chinese medicine prepn for treating women's disease and its prepn | |
| CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
| CN1943662A (en) | The Chinese traditional medicinal composition granules for treating galactophore disease and its preparation method and its products | |
| CN101926955B (en) | Medicament for treating stomach illness | |
| CN1742821A (en) | Blood-activating preparation and preparing method | |
| CN101032572A (en) | Sanguisorba huaijiao agent and the novel preparing method | |
| CN100337649C (en) | Medicine for treating rheumatic arthritis and its preparing method | |
| CN1628763A (en) | Cassia twig and Tuckahoe formulation for treating gynecological disease and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Zhengsheng Document name: Notification to Pay the Fees |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081008 Termination date: 20091223 |